Primary Site >> Pancreatic Cancer

Gene >> MUC16

  • 1986
  • 1988
  • 1989
  • 1991
  • 1994
  • 1996
  • 2001
  • 2008
  • 2009
  • 2010
  • 2011
  • 2012
  • 2013
  • 2014
  • 2015
  • 2016
  • 2017
  • 2018
Ref: Clinical significance of serum CA125 values in patients with cancers of the digestive system.
PMID: 3459357
Ref: [Clinical evaluation on an enzyme immunoassay kit for basic fetoprotein (BFP). (2) Comparison and combination of BFP with other tumor markers].
PMID: 2456040
Ref: Expression of CA125 in pancreatic carcinoma and chronic pancreatitis.
PMID: 3207606
Ref: Partial purification and characterization of CA19-9 antigen from the ascitic fluid of a patient with pancreatic cancer.
PMID: 2805338
Ref: Evaluation of TATI and other markers in solid tumors.
PMID: 1780686
Ref: [Early detection of pancreatic cancer by serum markers].
PMID: 7511183
Ref: [Sensitivity and specificity of tumor markers in cancer diagnosis].
PMID: 8691613
Ref: Solid and papillary neoplasms of the pancreas.
PMID: 8711936
Ref: Immunocytochemical analysis of cell lines derived from solid tumors.
PMID: 11668190
Ref: An original administration of ifosfamide given once every other week: a clinical and pharmacological study.
PMID: 18510176
Ref: The prevalence and nature of glycan alterations on specific proteins in pancreatic cancer patients revealed using antibody-lectin sandwich arrays.
PMID: 19377061
Ref: [A resected case of effective treatment with S-1/gemcitabine and Paclitaxel combination chemotherapy for advanced pancreatic cancer with peritoneal and liver metastases].
PMID: 19620816
Ref: Mucin glycosylation is altered by pro-inflammatory signaling in pancreatic-cancer cells.
PMID: 19714813
Ref: Identification of a biomarker panel using a multiplex proximity ligation assay improves accuracy of pancreatic cancer diagnosis.
PMID: 20003342
Ref: Markedly elevated CA19-9 associated with benign ovarian cyst and ascites.
PMID: 21686409
Ref: Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.
PMID: 20395854
Ref: A novel high-affinity human monoclonal antibody to mesothelin.
PMID: 20635390
Ref: Pathobiological implications of MUC16 expression in pancreatic cancer.
PMID: 22066010
Ref: Enhanced discrimination of malignant from benign pancreatic disease by measuring the CA 19-9 antigen on specific protein carriers.
PMID: 22220206
Ref: Differential gene expression analysis of peripheral blood mononuclear cells reveals novel test for early detection of pancreatic cancer.
PMID: 22820136
Ref: Mucin 16 is a functional selectin ligand on pancreatic cancer cells.
PMID: 22159147
Ref: Coexpression of MUC16 and mesothelin is related to the invasion process in pancreatic ductal adenocarcinoma.
PMID: 22320398
Ref: Mucin-based targeted pancreatic cancer therapy.
PMID: 22372499
Ref: Changes in the expression of serum markers CA242, CA199, CA125, CEA, TNF-alpha and TSGF after cryosurgery in pancreatic cancer patients.
PMID: 22456901
Ref: Tuberculous lymphadenopathy mimicking pancreatic neoplasm.
PMID: 22851977
Ref: Intraductal tubular neoplasms of the bile ducts.
PMID: 23073323
Ref: The role of mesothelin in tumor progression and targeted therapy.
PMID: 22721387
Ref: Mesothelin binding to CA125/MUC16 promotes pancreatic cancer cell motility and invasion via MMP-7 activation.
PMID: 23694968
Ref: Glycan elongation beyond the mucin associated Tn antigen protects tumor cells from immune-mediated killing.
PMID: 24039759
Ref: CA125 is superior to CA19-9 in predicting the resectability of pancreatic cancer.
PMID: 24146342
Ref: MicroRNA-200c modulates the expression of MUC4 and MUC16 by directly targeting their coding sequences in human pancreatic cancer.
PMID: 24204560
Ref: Clinical value of serum tumor markers CA19-9, CA125 and CA72-4 in the diagnosis of pancreatic carcinoma.
PMID: 24649344
Ref: Diagnosis of pancreatic carcinoma based on combined measurement of multiple serum tumor markers using artificial neural network analysis.
PMID: 24824251
Ref: Validation of biomarkers that complement CA19.9 in detecting early pancreatic cancer.
PMID: 25239611
Ref: Dilution effect of serum CA125 and CA19-9 over a cutoff value, according to obesity.
PMID: 25262704
Ref: Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
PMID: 25486903
Ref: Expression and diagnostic value of HE4 in pancreatic adenocarcinoma.
PMID: 25642754
Ref: Carboxyl-terminal domain of MUC16 imparts tumorigenic and metastatic functions through nuclear translocation of JAK2 to pancreatic cancer cells.
PMID: 25691062
Ref: MUC16-mediated activation of mTOR and c-Myc reprograms pancreatic cancer metabolism.
PMID: 26046375
Ref: Distinct kinetic and mechanical properties govern mucin 16- and podocalyxin-mediated tumor cell adhesion to E- and L-selectin in shear flow.
PMID: 26329844
Ref: The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreatic Cancer (CSPAC).
PMID: 26718269
Ref: DUSP28 links regulation of Mucin 5B and Mucin 16 to migration and survival of AsPC-1 human pancreatic cancer cells.
PMID: 27230679
Ref: [A Case of Early-Onset Rapidly Progressive Cerebral Infarction with Trousseau's Syndrome in a Patient with Pancreatic Cancer Undergoing Surgery].
PMID: 28133197
Ref: Cancer Antigen 125 (CA125, MUC16) Protein Expression in the Diagnosis and Progression of Pancreatic Ductal Adenocarcinoma.
PMID: 27093451
Ref: Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma.
PMID: 28108627
Ref: Galectin-3 is a non-classic RNA binding protein that stabilizes the mucin MUC4 mRNA in the cytoplasm of cancer cells.
PMID: 28262838
Ref: Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer.
PMID: 29132146
Ref: Amatuximab and novel agents targeting mesothelin for solid tumors.
PMID: 29184420
Ref: Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass.
PMID: 29171983
Ref: MUC16 C terminal-induced secretion of tumor-derived IL-6 contributes to tumor-associated Treg enrichment in pancreatic cancer.
PMID: 29337110
Ref: Detection and proteomic characterization of extracellular vesicles in human pancreatic juice.
PMID: 29550476
Ref: Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.
PMID: 29738555
Ref: Multilayered prevention and treatment of chronic inflammation, organ fibrosis and cancer associated with canonical WNT/betacatenin signaling activation (Review).
PMID: 29786110
Ref: Clean Colorectum at Diagnostic Colonoscopy: Subsequent Detection of Extracolonic Malignancies by Plasma Protein Biomarkers?
PMID: 29872358
Ref: MiR-29a, targeting caveolin 2 expression, is responsible for limitation of pancreatic cancer metastasis in patients with normal level of serum CA125.
PMID: 29978477
Ref: [Diagnosis and treatment experience of 161 cases of pancreatic serous cystic neoplasm in single center and analysis of cause of preoperation misjudgement].
PMID: 30107701
Ref: Integrative analysis of the cancer genome atlas and cancer cell lines encyclopedia large-scale genomic databases: MUC4/MUC16/MUC20 signature is associated with poor survival in human carcinomas.
PMID: 30236127
Ref: Protein Synthesis Inhibition Activity of Mesothelin Targeting Immunotoxin LMB-100 Decreases Concentrations of Oncogenic Signaling Molecules and Secreted Growth Factors.
PMID: 30384408